Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9800MR)

This product GTTS-WQ9800MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9800MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13665MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ10591MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ10977MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ6801MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ1389MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ5437MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ7618MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ8521MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW